EUVIMED · CrossrefJournal
Journal of Managed Care & Specialty Pharmacy
ISSN 2376-0540 · Academy of Managed Care Pharmacy
Latest articles
AMCP Market Insights: Managed care considerations in chronic inflammatory demyelinating polyradiculoneuropathy
AMCP Market Insights: Examining the current and future state of hemophilia B gene therapy in managed care
Advancing precision medicine access in oncology: Foundational considerations for managed care stakeholders
Natural language processing to develop a standardized lexicon for precision medicine in oncology
Payer coverage principles for precision medicine biomarker testing in oncology
Key considerations when assessing clinical utility for biomarker testing: A checklist
RAPID3 disease activity trajectory among patients with rheumatoid arthritis new to specialty pharmacy medications
Equivalent effectiveness of a prescription binocular treatment for amblyopia in real-world practice
Prevalence of renal and bone risk factors and nucleos(t)ide analogue treatment among patients with chronic hepatitis B in the United States
Piloting a specialty pharmacy turnaround time quality measure: Findings and lessons learned
Advancing the measurement of caregiver impact: Data collection priorities aligned with caregiver, health technology assessment, and policy stakeholders
Clinical harm from failure to deploy personalized medicine for patients with metastatic non–small cell lung cancer
Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model
Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey
Economic value of ribociclib in early breast cancer in the United States
Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy
Bundling medical and pharmacy benefits: Impact on medical costs
Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars
Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non–small cell lung cancer
Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening
Improving adherence to guideline-based lipid-lowering therapy in people with hyperlipidemia using a targeted educational outreach approach
Findings from the 2025 AMCP Foundation Symposium: Health Optimization 2.0
AMCP Market Insights: Managed care considerations in Barth syndrome
Call for improved workforce planning for pharmacists in all industries to sustain the profession
US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness
Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2–negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor era
The Washington State Prescription Drug Affordability Board’s selection of drugs for affordability review
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025)
Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years
The effectiveness and value of B-cell–directed therapies for the treatment of immunoglobulin A nephropathy
EUVIMED